相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Tomas Kalincik et al.
ANNALS OF NEUROLOGY (2015)
Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography
J. L. Bennett et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
David H. Miller et al.
NEUROLOGY (2015)
PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate
Dennis J. Nieuwkamp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
Thorsten Rosenkranz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography
J. L. Bennett et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview
Roberto Bomprezzi
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Relapses in patients treated with fingolimod after previous exposure to natalizumab
G. Comi et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model
Martin Stangel et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Glial cells express nuclear Nrf2 after fumarate treatment for multiple sclerosis and psoriasis (vol 2, e99, 2015)
I. Metz
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
UNMASKING AND PROVOKING SEVERE DISEASE ACTIVITY IN A PATIENT WITH NMO SPECTRUM DISORDER
Michael D. Kornberg et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis
Richard Nixon et al.
ADVANCES IN THERAPY (2014)
Update on Disease-Modifying Treatments for Multiple Sclerosis
Michael D. Carrithers
CLINICAL THERAPEUTICS (2014)
A Review of Safety-Related Pregnancy Data Surrounding the Oral Disease-Modifying Drugs for Multiple Sclerosis
Ellen Lu et al.
CNS DRUGS (2014)
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Amit Bar-Or et al.
DRUGS (2014)
Mode of action and clinical studies with fumarates in multiple sclerosis
Anke Salmen et al.
EXPERIMENTAL NEUROLOGY (2014)
Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis
Radu Tanasescu et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Multiple sclerosis and pregnancy prescriptions
Patricia K. Coyle
EXPERT OPINION ON DRUG SAFETY (2014)
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
Ralf Gold et al.
JOURNAL OF NEUROLOGY (2014)
Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
Corinna Trebst et al.
JOURNAL OF NEUROLOGY (2014)
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
T. L. Vollmer et al.
JOURNAL OF NEUROLOGY (2014)
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
Massimo Filippi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
Tomas Olsson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Is it time for a new global classification of multiple sclerosis?
Mario O. Melcon et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
Aaron E. Miller et al.
LANCET NEUROLOGY (2014)
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
Thomas P. Leist et al.
LANCET NEUROLOGY (2014)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Christian Confavreux et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Retinal nerve fibre layer thickness correlates with brain white matter damage in multiple sclerosis: A combined optical coherence tomography and diffusion tensor imaging study
Michael Scheel et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod
Robert Hoepner et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
ACTRIMS-ECTRIMS MSBoston 2014: Late Breaking News Oral Presentations
Multiple Sclerosis Journal (2014)
Fingolimod after natalizumab and the risk of short-term relapse
Vilija G. Jokubaitis et al.
NEUROLOGY (2014)
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis
Goeril Karlsson et al.
NEUROLOGY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
Luca Massacesi et al.
PLOS ONE (2014)
Switching From Natalizumab to Fingolimod in Multiple Sclerosis A French Prospective Study
Mikael Cohen et al.
JAMA NEUROLOGY (2014)
Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial
L. Kappos et al.
Multiple Sclerosis and Related Disorders (2014)
Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects
Jiwon Oh et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)
Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study
Katrin Strassburger-Krogias et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)
Cognitive impairment and invisible symptoms are not associated with CCSVI in MS
Carmela Leone et al.
BMC NEUROLOGY (2013)
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis
Valerie Jolivel et al.
BRAIN (2013)
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride
Tarunya Arun et al.
BRAIN (2013)
Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis
T. Komiya et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis
Karly P. Garnock-Jones
CNS DRUGS (2013)
Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis
R. A. Grove et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis
G. M. Hadjigeorgiou et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2013)
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Krzysztof Selmaj et al.
LANCET NEUROLOGY (2013)
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption
A. Laroni et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis
Francesca Ruffini et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome
Timm Oberwahrenbrock et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Fingolimod treatment in multiple sclerosis leads to increased macular volume
Rachel Nolan et al.
NEUROLOGY (2013)
Higher macular volume in patients with MS receiving fingolimod Positive outcome or side effect?
Marc Dinkin et al.
NEUROLOGY (2013)
Solving the dilemma of EEG misinterpretation
John W. Miller et al.
NEUROLOGY (2013)
PERIPHERAL NEUROPATHY DUE TO DINITROPHENOL USED FOR WEIGHT LOSS: SOMETHING OLD, SOMETHING NEW
Lauren Phillips et al.
NEUROLOGY (2013)
PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
Bob W. van Oosten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Manufacturer's Response to Case Reports of PML
Marianne T. Sweetser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PML in a Patient Treated with Fumaric Acid
Ummehan Ermis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Fingolimod Therapy for Multiple Sclerosis
Mary A. Willis et al.
SEMINARS IN NEUROLOGY (2013)
Efficacy and safety of laquinimod in multiple sclerosis: current status
Shalom Haggiag et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2013)
Teriflunomide in relapsing multiple sclerosis: therapeutic utility
Mark S. Freedman
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2013)
Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor
Jan Thoene et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
Patrick Vermersch et al.
BMC NEUROLOGY (2012)
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
P. Gergely et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis
Elias Toubi et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis
Rina Aharoni et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
New hands at the helm
Roger A. Barker
JOURNAL OF NEUROLOGY (2012)
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial
David H. Miller et al.
LANCET NEUROLOGY (2012)
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
Virginia Devonshire et al.
LANCET NEUROLOGY (2012)
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
Ju-Hong Min et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Sudden unexpected death on fingolimod
J. W. Lindsey et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years
Christian Confavreux et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Teriflunomide added to interferon-β in relapsing multiple sclerosis A randomized phase II trial
M. S. Freedman et al.
NEUROLOGY (2012)
Fatal PML associated with efalizumab therapy Insights into integrin αLβ2 in JC virus control
N. Schwab et al.
NEUROLOGY (2012)
DOES NATALIZUMAB THERAPY WORSEN NEUROMYELITIS OPTICA?
Anu Jacob et al.
NEUROLOGY (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy
Nadja Borisow et al.
EPMA JOURNAL (2012)
Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway
Robert H. Scannevin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
The Sphingosine-1-phospate receptor 1 mediates S1P action during cardiac development
Ryan R. Poulsen et al.
BMC DEVELOPMENTAL BIOLOGY (2011)
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Ralf A. Linker et al.
BRAIN (2011)
Cladribine: Mode of Action and Implications for Treatment of Multiple Sclerosis
Thomas P. Leist et al.
CLINICAL NEUROPHARMACOLOGY (2011)
Fingolimod A Review of its Use in the Management of Relapsing-Remitting Multiple Sclerosis
Lesley J. Scott
CNS DRUGS (2011)
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
Kamran Ghoreschi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis
D. G. MacManus et al.
JOURNAL OF NEUROLOGY (2011)
The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation
Luca Piali et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
Bhupendra Khatri et al.
LANCET NEUROLOGY (2011)
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
Gavin Giovannoni et al.
LANCET NEUROLOGY (2011)
Delayed fingolimod-associated asystole
Patricio S. Espinosa et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Beyond hairy cell: the activity of cladribine in other hematologic malignancies
Darren S. Sigal et al.
BLOOD (2010)
Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients
Trina A. Johnson et al.
CLINICAL IMMUNOLOGY (2010)
2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P1 Receptor Agonists
Martin H. Bolli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis
Christiane Wegner et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In-vitro high-throughput gene expression study
M. Gurevich et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Development of oral cladribine for the treatment of multiple sclerosis
Hans-Peter Hartung et al.
JOURNAL OF NEUROLOGY (2010)
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
G. Comi et al.
MULTIPLE SCLEROSIS (2010)
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study
G. Comi et al.
MULTIPLE SCLEROSIS (2010)
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Christoph Heesen et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Freedom from disease activity in multiple sclerosis
Eva Havrdova et al.
NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
Patrice Dubreuil et al.
PLOS ONE (2009)
Leflunomide-Associated Progressive Multifocal Leukoencephalopathy
Megan Rahmlow et al.
ARCHIVES OF NEUROLOGY (2008)
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
G. Comi et al.
LANCET (2008)
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
Ludwig Kappos et al.
LANCET (2008)
Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice
Ryou Fukushima et al.
REPRODUCTIVE TOXICOLOGY (2007)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor
Petr Vachal et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Oral fumaric acid esters for the treatment of active multiple sclerosis:: an open-label, baseline-controlled pilot study
S. Schimrigk et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
PW O'Connor et al.
NEUROLOGY (2006)
Pulmonary and vascular pharmacology of sphingosine 1-phosphate
Volker Brinkmann et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
Activation of the SPHK/SIP signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways -: art. no. 48
M Pfaff et al.
RESPIRATORY RESEARCH (2005)
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
C Polman et al.
NEUROLOGY (2005)
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders:: Structure-activity relationship
S Jönsson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats
HS Yang et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Pharmacokinetics of oral fumarates in healthy subjects
NHR Litjens et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis
JJ Hoefnagel et al.
BRITISH JOURNAL OF DERMATOLOGY (2003)
Dimethylfumarate is a potent inducer of apoptosis in human T cells
F Treumer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature
K Warnatz et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephomyelitis
C Brunmark et al.
JOURNAL OF NEUROIMMUNOLOGY (2002)
Exposure-disease continuum for 2-chloro-2′-deoxyadenosine (2-CdA), a prototype teratogen:: Induction of lumbar hernia in the rat and species comparison for the teratogenic responses
C Lau et al.
TERATOLOGY (2002)
The immune modulator FTY720 targets sphingosine 1-phosphate receptors
V Brinkmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue
LP Zou et al.
NEUROPHARMACOLOGY (2002)
Linomide in relapsing and secondary progressive MS - Part I: Trial design and clinical results
JH Noseworthy et al.
NEUROLOGY (2000)
Linomide in relapsing and secondary progressive MS -: Part II:: MRI results
JS Wolinsky et al.
NEUROLOGY (2000)
分享论文
